Criteria for grading on the CTCAE scale vary by toxicity, however by convention, grade 1 typically refers to asymptomatic or mild symptoms not requiring intervention, grade 2 refers to moderate symptoms that interfere somewhat with daily function and where some intervention may be indicated, and grade 3 refers to severe symptoms that interfere . 0000001178 00000 n }? 2015 Oct;95(4):361-4. doi: 10.1111/ejh.12570. 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. Monitor Closely (1)darunavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. The .gov means its official. Compare formulary status to other drugs in the same class. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Severe Acute Pulmonary Toxicity Associated with Brentuximab in a voxelotor will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. -, Bouchard Herv, Viskov Christian, Garcia-Echeverria Carlos. This site needs JavaScript to work properly. Monitor Closely (1)clarithromycin increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Monitor patients for adverse reactions. Poster PF305, 2020 by The American Society of Hematology, Copyright 2023 by American Society of Hematology, https://doi.org/10.1182/bloodadvances.2019001305, https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf, https://www.hcp.novartis.com/products/kymriah/diffuse-large-b-cell-lymphoma-adults/safety-profile/, Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL, Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL, Life-threatening consequences; urgent intervention indicated, Patient in critical condition, and/or obtunded and cannot perform assessment of tasks, Stage 1-2 papilledema, or CSF opening pressure <20 mm Hg, Stage 3-5 papilledema, or CSF opening pressure 20 mm Hg, or cerebral edema, Partial seizure, or nonconvulsive seizures on EEG with response to benzodiazepine, Generalized seizures, or convulsive or nonconvulsive status epilepticus, or new motor weakness, 0: patient is unarousable and unable to perform ICE, Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse. Either increases effects of the other by immunosuppressive effects; risk of infection. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Modify Therapy/Monitor Closely. CYP3A4 substrates may require dosage adjustment. 2018, Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Adjust dose of drugs that are CYP3A4 substrates as necessary. WARNING: Rarely, a serious (sometimes fatal) brain infection (Progressive Multifocal Leukoencephalopathy-PML) has occurred in people receiving this medication. Epub 2015 Feb 13. Contact the applicable plan Monitor patients for adverse reactions. A simplified grading scale derived from the CTCAE was also created.
